First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (LON:FBT - Get Free Report)'s share price reached a new 52-week high on Monday . The company traded as high as GBX 1,723.20 ($21.04) and last traded at GBX 1,723.20 ($21.04), with a volume of 519 shares changing hands. The stock had previously closed at GBX 1,702.60 ($20.79).
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Stock Performance
The business's fifty day moving average price is GBX 1,650.47 and its 200-day moving average price is GBX 1,590.06. The stock has a market capitalization of £5.14 billion and a PE ratio of -1,581.27. The company has a debt-to-equity ratio of 0.04, a current ratio of 9.42 and a quick ratio of 9.27.
About First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation
(
Get Free Report)
Forbidden Technologies plc develops and owns cloud-based video technology in the United Kingdom, North America, and internationally. It offers Forscene, a cloud based video post-production and publishing platform with various applications, such as editing, adding closed caption, graphics, metadata fast, remote viewing, collaboration, and publishing content.
Featured Stories
Before you consider First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation wasn't on the list.
While First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
